Centauri Therapeutics
Focus: Centauri Therapeutics is an early-stage UK-based biotech specializing in Alphamers technology, a novel drug modality platform. The company is pre-revenue and in Series A funding stage with minimal commercial infrastructure.
Profile data last refreshed 1h ago · AI intelligence enriched 2mo ago
Funding Stage
SERIES A
Open Jobs
1+1 this month
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Should You Work at Centauri Therapeutics?
AI assessmentCentauri is a speculative early-stage bet suitable only for risk-tolerant scientists seeking to pioneer a novel modality, not for those requiring stability or near-term career advancement.
Why Work Here
- Ground-floor opportunity to build a novel technology platform (Alphamers) from early stage with potential for significant upside
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
DynaSense sensor
Pressure UlcersClinical Trials (1)
NCT02005692A Pilot Study to Assess the DynaSense System
N/AHelp build intelligence for Centauri Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.